StarZero All shows Try the podcast clipper →

Chris Gibson

Operating Partner, Dimension Capital · 1 appearance on the record.

computed by AI from the episodes · how this works → · full disclaimer →

founderexecutiveinvestorengineerLinkedIn ↗recursion.com ↗

Gibson co-founded Recursion Pharmaceuticals in 2013, pioneering TechBio by combining automated cellular imaging and machine learning to map biology, leading the company through its 2021 NASDAQ IPO. Under his tenure, Recursion formed major partnerships with Roche, Bayer, and NVIDIA, and completed a $688 million merger with Exscientia.

5statements → 1claims → 1claims resolved → 4/5average certainty → 1.2/5average debate potential → 1said about them ↓

1 supported 0 partly supported 0 contradicted how the 1 claim stands · each chip opens the sources

1 assertion · 1 insight · 3 disclosures · every statement was checked. The predictions and assertion are the 1 claim: statements the public record can support or contradict. 1 is resolved. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Chris argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Assertion Supported
Gibson: Recursion raised $19M in equity and $5-6M in non-dilutive grants
“Yeah, we've raised about nineteen million dollars in, in equity financing, and then another five or six million in sort of non-dilutive funds from small business grants from the NIH, and then a number of private foundations as well.”
Chris Gibson Apr 17, 2017 ▶ 10:36 632: Recursion enzyme company raises $23M, launched in 2013 now 40 people with drugs ready for market with CEO Christopher Gibson

How they sound: not measured why? →

We measure speaking style by listening to the audio itself, and a fair number needs at least 2,000 words from one person on tape we have measured. There is too little of Chris Gibson on measured tape to publish a rate. This says nothing about how they speak.

Everything Chris Gibson said on Top Founders that made the record, most notable first. Filter by type, assessment or year in the ledger →

Insight
Gibson: Traditional life sciences investors value single assets over platforms
“So we are a platform company, and in our particular space, that's in life sciences, that's actually not the language that people speak in terms of value. They speak in terms of assets. And so that was one of the real challenges for us in terms of raising money…”
Chris Gibson Apr 17, 2017 ▶ 11:27 632: Recursion enzyme company raises $23M, launched in 2013 now 40 people with drugs ready for market with CEO Christopher Gibson
Disclosure
Gibson: Recursion partnered with Sanofi Genzyme to repurpose shelved drugs
“We've announced, for example, a partnership with Sanofi Genzyme, and in that particular case, we have drugs that, that they spent decades working on in many cases, and those drugs never ended up making it to patients, not because they're bad drugs, just becaus…”
Chris Gibson Apr 17, 2017 ▶ 2:44 632: Recursion enzyme company raises $23M, launched in 2013 now 40 people with drugs ready for market with CEO Christopher Gibson
Disclosure
Gibson: Recursion is eight months from clinical trials for CCM
“We also have an internal pipeline of drugs that we're developing ourselves one of those is just about eight months away from clinical trials now for a disease called cerebral cavernous malformation.”
Chris Gibson Apr 17, 2017 ▶ 4:20 632: Recursion enzyme company raises $23M, launched in 2013 now 40 people with drugs ready for market with CEO Christopher Gibson
Disclosure
Gibson: Recursion is negotiating eight-figure upfront biotech partnership deals
“And then there's partnerships we're negotiating now that are eight figures upfront.”
Chris Gibson Apr 17, 2017 ▶ 6:34 632: Recursion enzyme company raises $23M, launched in 2013 now 40 people with drugs ready for market with CEO Christopher Gibson
Assertion Supported
Gibson: Recursion raised $19M in equity and $5-6M in non-dilutive grants
“Yeah, we've raised about nineteen million dollars in, in equity financing, and then another five or six million in sort of non-dilutive funds from small business grants from the NIH, and then a number of private foundations as well.”
Chris Gibson Apr 17, 2017 ▶ 10:36 632: Recursion enzyme company raises $23M, launched in 2013 now 40 people with drugs ready for market with CEO Christopher Gibson

The other half of the tape: Chris Gibson's own voice is left out of every number here. Other people bring the name up 1 time in 1 episode on Top Founders. every mention, with the transcript →

Who brings them up most Nathan Latka 1

Every mention by year

tap a year for its mentions
0011112017episodesmentions
0112017episodes it came up in
000.50.5112017episodesmentions per episode
2017 1 mention in 1 episode

Appearances (1)

EpisodeDateSpeaking time
632: Recursion enzyme company raises $23M, launched in 2013 now 40 people with drugs ready Apr 17, 2017 8m
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 2,600 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more